Results 61 to 70 of about 590 (119)

Matching-Adjusted Indirect Comparison of the Efficacy at Week 32 of Tralokinumab and Dupilumab in the Treatment of Moderate-to-Severe Atopic Dermatitis

Dermatology and Therapy
Introduction Tralokinumab and dupilumab are biological agents licensed for the treatment of moderate-to-severe atopic dermatitis (AD) in adult patients who are candidates for systemic treatment.
Tiago Torres, Anne Sohrt Petersen, Ulla Ivens, Albert Bosch Vilaro, John Stinson, José Manuel Carrascosa   +5 more
doaj   +1 more source

Successful treatment of Hailey–Hailey disease (HHD) with the IL‐13 inhibitor lebrikizumab

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Elena Schneider, Maike M. Holtsche, Ulrike Raap, Nikolaos Patsinakidis   +3 more
wiley   +1 more source

Minimal Disease Activity as A New Therapeutic Target in Atopic Dermatitis: A 5‐Year Real‐Life Experience With Dupilumab

International Journal of Dermatology, Volume 65, Issue 9, Page 1846-1855, September 2026.
ABSTRACT Background Atopic dermatitis (AD) is a chronic inflammatory skin disease with significant physical and psychosocial burden. Dupilumab, a monoclonal antibody targeting IL‐4Rα, has proven to be effective for moderate‐to‐severe AD, but long‐term real‐world data remain limited.
Francesco Leo, Luca Mastorino, Luca Cangialosi, Davide Favre, Chiara Anna Fiasconaro, Yingying Liao, Federico Goso, Niccolò Siliquini, Giovanni Cavaliere, Pietro Quaglino, Simone Ribero, Michela Ortoncelli   +11 more
wiley   +1 more source

Real‐life case‐series experience with tralokinumab in patients with severe atopic dermatitis

JEADV Clinical Practice
Atopic dermatitis (AD) is an inflammatory chronic recurrent skin condition that causes recurrent, itching eczematous lesions with a great impact on the quality of life of patients.
Francesca Caroppo, Anna Belloni Fortina
doaj   +1 more source

Evidence Summary of Pruritus Management in Patients With Atopic Dermatitis: Implications for Nursing Practice

Journal of Cosmetic Dermatology, Volume 25, Issue 9, September 2026.
ABSTRACT Background To synthesize the most current and relevant evidence regarding pruritus management in patients with atopic dermatitis (AD), and to identify implications for nursing assessment, education, monitoring, and follow‐up. Method An extensive literature search was conducted across multiple databases, including the Cochrane Library, Embase ...
Yuzhen Shen, Qian Shen, Manni Chen, Rufang Liu   +3 more
wiley   +1 more source

Update on biologic and small molecules treatments in pediatric allergic diseases

Pediatric Allergy and Immunology, Volume 37, Issue 9, September 2026.
This graphical abstract summarizes key targets, mechanisms of action, and indications of biologic and small molecules treatments in pediatric allergic diseases.abbreviations : BAS, basophil; BTK, Bruton tyrosine kinase; cDC, conventional dendritic cell; IgE, immunoglobulin E; FCER1, high affinity IgE receptor; IL, interleukin; IL4R, IL4 receptor; JAK ...
Herman T. den Dekker, Amandine Divaret Chauveau, Benoit Sterling, Stéphanie Coopman, R. Sharon Chinthrajah, Stéphanie Lejeune, Dorothea Holter, Thomas Eiwegger, Stéphanie Mallet, Mariëlle W. Pijnenburg, Antoine Deschildre   +10 more
wiley   +1 more source

Treatment of atopic dermatitis with tralokinumab, an anti–IL-13 mAb

, 2019
© 2018 The Authors Background: IL-13 has an important role in atopic dermatitis (AD) pathogenesis. Tralokinumab is a fully human mAb that potently and specifically neutralizes IL-13.
Christopher Kell, Andreas Wollenberg, Koustubh Ranade, Kell, Christopher, Wollenberg, Andreas, René van der Merwe, Silverberg, Jonathan I., Rachel Moate, Guttman-Yassky, Emma, Michael D. Howell, Moate, Rachel, Emma Guttman-Yassky, van der Merwe, René, Ranade, Koustubh, Jonathan I. Silverberg, Howell, Michael D.   +15 more
core   +1 more source

Lack of Differences in the Pharmacokinetics of Therapeutic Monoclonal Antibodies Between Japanese and Non‐Japanese Individuals

The Journal of Clinical Pharmacology, Volume 66, Issue 8, August 2026.
Abstract Evaluation of the pharmacokinetics (PK) of new drugs in Japanese individuals is regularly requested by the Japanese regulatory agency prior to participation in global clinical trials or for bridging approaches for regulatory approval. However, the need for PK assessments in the Japanese population may be less compelling for monoclonal ...
Paridhi Gupta, Ashish Sharma, Bernd Meibohm   +2 more
wiley   +1 more source

Modern treatment methods in atopic dermatitis - literature overview

Journal of Education, Health and Sport
Introduction and aim: Atopic dermatitis (AD) is a chronic inflammatory skin disease. It is characterised by periods of exacerbation and remission of symptoms such as pruritus, dry skin and eczematous lesions with characteristic morphology.
Martyna Borowska-Łygan, Jakub Tomaszewski, Wojciech Urban, Konrad Strużek, Jan Biłogras, Kornelia Karamus, Rafał Wojciech Rejmak   +6 more
doaj   +1 more source

Application of structured statistical analyses to identify a biomarker predictive of enhanced tralokinumab efficacy in phase III clinical trials for severe, uncontrolled asthma

BMC Pulmonary Medicine, 2019
Background Tralokinumab is an anti–interleukin (IL)-13 monoclonal antibody investigated for the treatment of severe, uncontrolled asthma in two Phase III clinical trials, STRATOS 1 and 2.
Mattis Gottlow, David J. Svensson, Ilya Lipkovich, Monika Huhn, Karin Bowen, Peter Wessman, Gene Colice   +6 more
doaj   +1 more source